Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 15 January 2015 | By Alexander Gaffney, RAC,
The US Food and Drug Administration's Center for Drug Evaluation and Research (CDER) is already off to a busy start this year, having released new long-sought functions on its website, launched its new Office of Pharmaceutical Quality (OPQ) and hired a permanent director for its Office of Generic Drugs.
The changes, it seems, aren't stopping there. Last week, CDER also announced a reorganization of its Office of Management in the hopes of streamlining its approach to managing the nation's drug regulators.
In an email to FDA staff on 8 January 2015, CDER Director Janet Woodcock said the new management staff will include two additions: a strategic programs and initiatives staff, and an ethics liaison staff.
The overall will also see the creation of two new divisions:
A third division, the Division of Management Services (DMS), which oversees most of CDER's HR functions, will continue to exist with some minor changes. CDER also said it plans to eliminate a total of six branches:
Woodcock said the reorganization will help CDER to "better meet the management services needs of a growing Center with expanding authorities" under the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012.
Tags: Office of Management, Janet Woodcock